In focus · trending topic

(LID)

2 stories · following the connections

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

By Nasdaq OMXJan 6, 2017, 2:01 PM UTC

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

By Nasdaq OMXJan 6, 2017, 2:01 PM UTC